- AU$35.17m
- AU$30.06m
- AU$0.51m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.57 | ||
| Price to Tang. Book | 4.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 44.11 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -111.9% | ||
| Return on Equity | -140.07% | ||
| Operating Margin | -1413.13% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.3 | 0.9 | 0.76 | 0.41 | 0.51 | n/a | n/a | 27.93% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AnteoTech Limited is an Australia-based company engaged in providing solutions for the clean energy and life sciences markets using applied materials technology. The principal activities of the Company consist of development and commercialization of nanotechnologies with surface management applications. The Company’s lead product, Anteo X, provides significant improvement in anode performance and the Company partners with global suppliers in lithium-ion battery manufacturing. Its clean energy technology (CET) technologies improve the energy densities, cycle life and cost- effectiveness of lithium-ion batteries. The Company has two programs underway: Anteo X, its binder additive and the High Silicon Anode technology. The Life Sciences division services the point-of-care and in vitro diagnostics markets from global diagnostics companies to technology developers. Its AnteoBind provides advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.
Directors
- John Hamilton NEC
- Derek Thomson CEO
- Tim Pritchard CFO
- Nobuyoshi Maeji CSO
- Christopher Parker EDR
- Geoffrey Cumming NED
- Glenda McLoughlin NID (51)
- Katherine Wood NID (36)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 26th, 1995
- Public Since
- April 11th, 2000
- No. of Shareholders
- 9,383
- No. of Employees
- 40
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 2,705,300,325
- Address
- Brisbane Technology Park, EIGHT MILE PLAINS, 4113
- Web
- https://www.anteotech.com/
- Phone
- +61 732190085
- Auditors
- BDO Audit Pty Ltd
Upcoming Events for ADO
Similar to ADO
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Anteotech share price?
As of Today at 24:18 UTC, shares in Anteotech are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the Anteotech share price performed this year?
Shares in Anteotech last closed at AU$0.01 and the price had moved by -34.46% over the past 365 days. In terms of relative price strength the Anteotech share price has underperformed the ASX All Ordinaries Index by -40.11% over the past year.
What are the analyst and broker recommendations for Anteotech?
The overall consensus recommendation for Anteotech is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Anteotech dividend yield?
Anteotech does not currently pay a dividend.
Does Anteotech pay a dividend?
Anteotech does not currently pay a dividend.
When does Anteotech next pay dividends?
Anteotech does not currently pay a dividend.
How do I buy Anteotech shares?
To buy shares in Anteotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Anteotech?
As of the previous close price of AU$0.01, shares in Anteotech had a market capitalisation of AU$35.17m.
Where are Anteotech shares listed?
Here are the trading details for Anteotech:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ADO
What kind of share is Anteotech?
Based on an overall assessment of its quality, value and momentum Anteotech is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Anteotech share price forecast for 2025?
The analyst consensus target price for shares in Anteotech is AU$0.38. That is 2823.08% above the last closing price of AU$0.01.
Analysts covering Anteotech currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Anteotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Anteotech. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -34.1%.
As of the last closing price of AU$0.01, shares in Anteotech were trading -18.66% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Anteotech PE Ratio?
The Anteotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Anteotech?
Anteotech's management team is headed by:
- John Hamilton - NEC
- Derek Thomson - CEO
- Tim Pritchard - CFO
- Nobuyoshi Maeji - CSO
- Christopher Parker - EDR
- Geoffrey Cumming - NED
- Glenda McLoughlin - NID
- Katherine Wood - NID